Caribou Biosciences(CRBU)
$0.33-0.01 (-4.12%)
CRBU
Caribou Biosciences stock drug pipeline
$0.33
At close:-0.01 (-4.12%)
Want to see CRBU full AI Analyst Report?
Caribou Biosciences (CRBU) Drug Pipeline
1,002 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cb-010 | Lupus Nephritis, Systemic Lupus Erythematosus, Lupus Erythematosus, Lupus | Phase I | Withdrawn | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) | Dec 18, 2024 | ― |
| Cb-012 | Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, In Relapse | Phase I | Terminated | CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Nov 06, 2023 | ― |
| Cb-011 | Relapsed/Refractory Multiple Myeloma | Phase I | Recruiting | CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | Dec 19, 2022 | ― |
| Cyclophosphamide, Fludarabine, Cb-010 | Lymphoma, Non Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, B Cell Lymphoma, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, B Cell Non-Hodgkin's Lymphoma | Phase I | Recruiting | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) | Nov 16, 2020 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cb-010 | Phase I | Lupus Nephritis, Systemic Lupus Erythematosus, Lupus Erythematosus, Lupus | Withdrawn | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) | Dec 18, 2024 | ― |
| Cb-012 | Phase I | Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, In Relapse | Terminated | CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Nov 06, 2023 | ― |
| Cb-011 | Phase I | Relapsed/Refractory Multiple Myeloma | Recruiting | CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | Dec 19, 2022 | ― |
| Cyclophosphamide, Fludarabine, Cb-010 | Phase I | Lymphoma, Non Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, B Cell Lymphoma, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, B Cell Non-Hodgkin's Lymphoma | Recruiting | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) | Nov 16, 2020 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Caribou Biosciences, Inc. (CRBU) have in its pipeline
Caribou Biosciences CRBU is currently developing the following drugs: Cb-010, Cb-012, Cb-011, Cyclophosphamide, Fludarabine, Cb-010. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

